Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera(®) was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera(®) combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Hennrich, Ute, Kopka, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789871/
https://www.ncbi.nlm.nih.gov/pubmed/31362406
http://dx.doi.org/10.3390/ph12030114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789871/
https://www.ncbi.nlm.nih.gov/pubmed/31362406
http://dx.doi.org/10.3390/ph12030114

Ejemplares similares